Skip to main content
TAKARA BIO INC. logo

TAKARA BIO INC. — Investor Relations & Filings

Ticker · 4974 ISIN · JP3460200003 LEI · 529900OUPLSGTCWC5447 T Manufacturing
Open in API
Filings indexed 72 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country JP Japan
Listing T 4974

About TAKARA BIO INC.

https://www.takarabio.com/?srsltid=AfmB…

Takara Bio Inc. is a biotechnology company that develops and supplies a wide range of high-quality, innovative tools for life science research. Its portfolio includes kits, reagents, and instruments that support investigations into gene discovery, regulation, and function. In addition to research products, the company provides comprehensive services, including single-cell analysis, stem cell services, and contract development and manufacturing (CDMO) services, particularly for the regenerative medicine sector. Takara Bio is also actively engaged in the development of gene-based therapies, conducting clinical trials for diseases such as cancer. The company's mission is to accelerate scientific discovery and contribute to human health through its advanced biotechnologies.

Recent filings

Filing Released Lang Actions
臨時報告書
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Japanese “臨時報告書” (Extraordinary Report) filed under the Financial Instruments and Exchange Act, disclosing the resolutions approved at a special shareholders’ meeting – specifically a share consolidation and related amendments to the articles of incorporation – and including detailed vote counts. This falls squarely under “Declaration of Voting Results & Voting Rights Announcements” (DVA) as it is the official publication of shareholder vote results.
2026-05-21 Japanese
株式併合並びに単元株式数の定めの廃止及び定款の一部変更に係る承認決議に関するお知らせ
Share Issue/Capital Change Classification · 85% confidence The document is an official corporate announcement from Takara Bio regarding the approval of share consolidation (reverse stock split), the abolition of unit share requirements, and related amendments to the company’s articles of incorporation following an extraordinary shareholders’ meeting. This relates to a capital structure change rather than a financial report or proxy solicitation. Under the classification schema, announcements of stock consolidations or other capital changes fall under Share Issue/Capital Change (SHA).
2026-05-20 Japanese
臨時報告書
Share Issue/Capital Change Classification · 85% confidence The document is a Japanese 臨時報告書 (“Extraordinary Report”) filed with the Kanto Finance Bureau on April 27, 2026 by Takara Bio Inc. The board has resolved to convene an extraordinary shareholders’ meeting for a share consolidation (reverse split) to effect a squeeze-out following a tender offer by the parent. Although it provides extensive background on the takeover offer and fairness deliberations, its core purpose is to announce a capital structure change (share consolidation). Under our scheme, announcements of share splits/consolidations and other capital changes fall under the Share Issue/Capital Change category (SHA).
2026-04-27 Japanese
株式併合並びに単元株式数の定めの廃止及び定款の一部変更に関する臨時株主総会開催のお知らせ
Regulatory Filings
2026-04-27 Japanese
自己株式の消却に関するお知らせ
Regulatory Filings
2026-04-27 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under Article 24-5-2 of the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of the semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a report (in this case, the semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements. H1 2025
2025-11-12 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.